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Introduction
The pathogenesis of  type 1 diabetes (T1D) involves the development of  β cell autoimmunity, marked by the 
development of  circulating autoantibodies (aAbs) against β cell antigens, and declining insulin secretion. 
Longitudinal findings from the Diabetes Prevention Trial - Type 1 (DPT-1) showed that aAb-positive (Ab+) 
individuals had an acceleration in the decline of  the first-phase insulin response (1), the early C-peptide 
response (30- to 0-minute difference) (2), and β cell glucose sensitivity (3) 1–2 years prior to the diagnosis 
of  T1D. However, since the DPT-1 study mostly followed individuals within 3 years of  diagnosis, little is 
BACKGROUND. The duration and patterns of β cell dysfunction during type 1 diabetes (T1D) 
development have not been fully defined.
METHODS. Metabolic measures derived from oral glucose tolerance tests (OGTTs) were compared 
between autoantibody-positive (aAb+) individuals followed in the TrialNet Pathway to Prevention 
study who developed diabetes after 5 or more years or less than 5 years of longitudinal follow-up 
(Progressors≥5, n = 75; Progressors<5, n = 474) and 144 aAb-negative (aAb–) relatives.
RESULTS. Mean age at study entry was 15.0 ± 12.6 years for Progressors≥5; 12.0 ± 9.1 for 
Progressors<5; and 16.3 ± 10.4 for aAb– relatives. At baseline, Progressors≥5 already exhibited 
significantly lower fasting C-peptide (P < 0.01), C-peptide AUC (P < 0.001), and early C-peptide 
responses (30- to 0-minute C-peptide; P < 0.001) compared with aAb– relatives, while 2-hour 
glucose (P = 0.03), glucose AUC (<0.001), and Index60 (<0.001) were all higher. Despite significant 
baseline impairment, metabolic measures in Progressors≥5 were relatively stable until 2 years prior 
to T1D diagnosis, when there was accelerated C-peptide decline and rising glycemia from 2 years 
until diabetes diagnosis. Remarkably, patterns of progression within 3 years of diagnosis were 
nearly identical between Progressors≥5 and Progressors<5.
CONCLUSION. These data provide insight into the chronicity of β cell dysfunction in T1D and indicate 
that β cell dysfunction may precede diabetes diagnosis by more than 5 years in a subset of aAb+ 
individuals. Even among individuals with varying lengths of aAb positivity, our findings indicate 
that patterns of metabolic decline are uniform within the last 3 years of progression to T1D.
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known about patterns of  metabolic decline in aAb+ individuals over longer periods of  follow-up. Analysis 
of  data from individuals who underwent extended observation prior to diagnosis would yield information 
about the potential chronicity of  metabolic abnormalities and lend further insight into long-term patterns 
of  metabolic decline during early stages of  T1D.
Since 2004, over 180,000 relatives of  individuals with T1D have been screened for the presence of  
islet aAbs as part of  the international Type 1 Diabetes TrialNet Pathway to Prevention (PTP) study. Over 
5,000 individuals have been identified as aAb+ and enrolled for longitudinal monitoring with either annual 
or biannual oral glucose tolerance testing, providing a unique opportunity to analyze natural history data 
from a large and geographically diverse at-risk aAb+ cohort of  individuals with variable and often long 
durations of  follow-up (4). Within this cohort, we studied a subset of  75 aAb+ individuals who progressed 
to T1D after a minimum of  5 years of  follow-up. This length of  follow-up was conducive for assessing the 
chronicity of  β cell dysfunction prior to diagnosis and provided an opportunity to study patterns of  β cell 
deterioration over a much longer period of  progression compared with prior natural history studies.
Results
Progressors with 5 or more years of  follow-up (Progressors≥5) were monitored for 6.6 ± 1.3 years from 
baseline oral glucose tolerance test (OGTT) to T1D diagnosis. They represented 13.7% (75 of  549) of  
all analyzed T1D cases within the study cohort: 12% were single aAb+, and 88% were multiple aAb+ at 
enrollment (Figure 1 and Supplemental Table 1; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.120877DS1).
Comparison of  baseline metabolic measures between Progressors≥5 and aAb– relatives. To assess the duration 
and extent of  β cell dysfunction prior to the onset of  T1D, we compared baseline metabolic data between 
75 aAb+ Progressors≥5 and 144 aAb-negative relatives (aAb–) who agreed to undergo OGTT testing after 
negative screening for aAbs. Supplemental Table 1 shows the baseline characteristics of  the Progressors≥5 
and aAb– participants. Progressors≥5 were younger (P = 0.01 for pairwise comparison) and had lower BMI 
Z-score values (P = 0.03 for pairwise comparison). Otherwise, there were no significant differences in gen-
der, race, ethnicity, or relationship to the T1D proband. At their baseline OGTTs, after adjustments for age 
and BMI Z score, Progressors≥5 had already demonstrated significant reductions in the fasting C-peptide 
(P < 0.01), the early C-peptide response (P < 0.001), and C-peptide AUC (P < 0.001) compared with the 
aAb– group. Consistent with these changes, the glucose AUC (P < 0.001), 2-hour glucose (P = 0.03), and 
Index60 (P < 0.001) were all significantly higher in Progressors≥5. Fasting glucose levels did not differ 
between the groups (Table 1).
Longitudinal patterns of  metabolic decline in Progressors≥5. Figure 2 shows the mean values of  the fasting 
C-peptide, early C-peptide response, C-peptide AUC, fasting glucose, 2-hour glucose, glucose AUC, and 
Index60 at baseline and then each year (±6 months) from 4 years to diagnosis for Progressors≥5. Also 
shown for reference are mean values of  the aAb– individuals at baseline (red dotted line). Again, evident 
are the marked differences at baseline between Progressors≥5.0 and aAb–participants. Although the num-
bers vary between the time points, the figure suggests a consistent pattern of  metabolic decline. This pattern 
was notable for the presence of  substantial metabolic abnormalities that were already present on average 
6.6 ± 1.3 years before diagnosis. However, there was relatively little change in these metabolic indices 
until approximately 2 years before diagnosis. Marked decreases in C-peptide and increases in glucose then 
became apparent, especially during the last year before diagnosis. An exception was the C-peptide AUC, 
which tended to increase after baseline and then declined just prior to diagnosis.
To examine this pattern quantitatively, we analyzed the absolute and percentage changes from baseline 
to 4 years before diagnosis, 4 years to 1 year before diagnosis, and 1 year to diagnosis (Table 2). The analysis 
included only those with paired OGTTs at the boundaries for each interval. From baseline (6.6 ± 1.3 years) 
to 4 years, the fasting glucose (P = 0.02) and glucose AUC (P = 0.03) increased significantly. However, there 
were no significant changes in the early C-peptide response, the C-peptide AUC, or the Index60 during this 
time period. Counter to what might be expected, the fasting C-peptide increased (P = 0.001).
More appreciable changes in the selected metabolic indices were observed between 4 years and 1 year 
prior to diagnosis (Table 2). During this time period, all measures of  glycemia significantly increased, 
including the fasting glucose (P = 0.01), 2-hour glucose (P = 0.002), glucose AUC (P = 0.01), and Index60 
(P = 0.004). The fasting C-peptide continued to increase (P = 0.01); however, there was no significant 
change in the early C-peptide response or the C-peptide AUC.
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As shown in Figure 2, there was marked metabolic deterioration from 1 year prior to the time 
of  diagnosis (Table 2). During this terminal period, the early C-peptide response (P < 0.001) and the 
C-peptide AUC (P = 0.01) significantly declined, while the fasting glucose, 2-hour glucose, glucose 
AUC, and Index60 (all P < 0.001) significantly increased. The fasting C-peptide continued to increase, 
but not to a significant extent (P = 0.13).
Comparisons of  changes between Progressors≥5 and Progressors followed less than 5 years. To address whether 
patterns of  β cell dysfunction were fundamentally different between Progressors≥5 and aAb+ PTP partici-
pants with less than 5 years of  follow-up (Progressors<5), we compared metabolic indices between these 
groups from study entry until T1D diagnosis. Compared with Progressors<5, Progressors≥5 were older at 
study entry (15.0 ± 12.6 years vs. 12.0 ± 9.1 years; P = 0.01) and at diagnosis (21.6 ± 12.8 years vs. 13.9 ± 
9.3 years; P < 0.001). The mean follow-up for Progressors≥5 was 6.6 ± 1.3 years, compared with a mean 
follow-up for Progressors<5 of  1.9 ± 1.3 years. Progressors≥5 had a lower BMI Z score at study entry with 
a median value of  0.41 (interquartile range [IQR]: –0.31 to 1.14) versus Progressors<5 who had a median 
BMI Z score of  0.69 (IQR: 0.04 to 1.46; P = 0.04 for pairwise comparison). The percentage of  Progressors≥5 
and Progressors<5 who were positive for a single aAb or were multiple-aAb positive at study entry was 
similar. Supplemental Table 2 shows comparisons of  metabolic data at study entry for Progressors≥5 and 
Progressors<5. As expected since Progressors<5 were closer to T1D diagnosis, they exhibited significantly 
Figure 1. Participant flow through the Type 1 Diabetes TrialNet Pathway to Prevention Study.
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lower fasting C-peptide levels (P = 0.048) and higher fasting glucose (P = 0.005), 2-hour glucose (P < 0.001), 
glucose AUC (P = 0.002), and Index60 values (P = 0.002). However, no differences were observed in the 
C-peptide AUC or early C-peptide responses.
To test whether longitudinal patterns of  metabolic decline were different between these 2 groups, 
mean values of  metabolic measures at 3 years (±6 months), 2 years (±6 months), and 1 year (±6 months) 
prior to T1D diagnosis were compared in the Progressors≥5 and Progressors<5 (Table 3). Remarkably, 
there were no significant differences in the mean values of  fasting glucose, 2-hour glucose, glucose AUC, 
fasting C-peptide, C-peptide AUC, early C-peptide response, or Index60 between the 2 groups at any of  
the time points tested. Next, we compared the absolute and percentage changes in these metabolic mea-
sures between Progressors≥5 and Progressors<5 from 3 years to 1 year before diagnosis and from 1 year 
to diagnosis. Similar to analysis of  mean values (Table 3), no significant difference in either the absolute 
or percentage change for each of  the analyzed metabolic measures was observed between the 2 groups 
(Supplemental Table 3).
Finally, to address whether severity of  metabolic dysfunction was different between these groups at the 
time of  T1D diagnosis, mean values of  the same metabolic variables were compared in Progressors≥5 and 
Progressors<5 who underwent an OGTT at the time of  T1D diagnosis. Fasting C-peptide and C-peptide 
AUC values were lower in the Progressors<5 (P < 0.001). However, following adjustment for age and BMI 
Z score, no significant differences in any of  the measures were observed. (Supplemental Table 4).
Discussion
Findings from this analysis of  aAb+ individuals followed longitudinally for 5 or more years in the TrialNet 
PTP study can be viewed according to 3 metabolic phases of  T1D progression. The first phase was marked 
by appreciable metabolic impairment at baseline (on average over 6 years before diagnosis), especially with 
regard to early C-peptide indices. It is unclear, however, when these abnormalities first occur, as subjects 
were recruited into the cohort after the development of  aAb positivity. During the second phase, span-
ning from study entry to approximately 2 years before diagnosis, there was relatively little change in either 
C-peptide or glucose indices. Finally, a third phase was evident during the last 2 years, in which there was 
accelerated metabolic deterioration, characterized by rising glycemia and worsening C-peptide secretion. 
Since the 3-phase model could be a function of  the study population, data limitations, and the analytic con-
struct, it is not definitive. Still, a consideration of  the model raises several fundamental questions regarding 
the pathogenesis of  T1D.
First metabolic phase. At study entry, Progressors≥5 already demonstrated significant differences in the 
majority of  C-peptide and glucose measures. Especially prominent were impairments in the early C-peptide 
response, which were approximately 40% lower in Progressors≥5 compared with the aAb– controls. Simi-
lar findings were seen in the Type I Diabetes Prediction and Prevention (DIPP) study, which followed Finn-
ish children with high-risk HLA alleles before and after seroconversion. Intravenous GTTs performed at the 
time of  initial seroconversion showed that 42% of  52 children with newly identified islet cell aAb positivity 
already had first-phase insulin responses (FPIRs) below the fifth percentile (5). These data suggest that loss 
of  early C-peptide responses are among the first and most identifiable defects in at-risk individuals. As to 
how these defects occur are a matter of  speculation. It is possible that immune activation caused a quantum 
Table 1. Comparison of metabolic parameters between Progressors≥5 and aAb– relatives at study entry
Progressors≥5 (n = 75) Mean (SD) aAb– Controls (n = 144) Mean (SD) P valueA P valueB
Fasting C-peptide (ng/ml) 1.31 (0.68) 1.72 (0.83) <0.001 <0.001
Early C-peptide Response (ng/ml) 2.95 (1.65) 4.89 (2.29) <0.001 <0.001
C-peptide AUC (mg/dl/120 min) 4.85 (2.23) 6.64 (2.43) <0.001 <0.001
Fasting Glucose (mg/dl) 87.31 (9.07) 89.37 (7.38) 0.09 0.11
2-hour Glucose (mg/dl) 118.84 (28.64) 111.14 (25.9) 0.045 0.03
Glucose AUC 136.2 (22.02) 125.6 (23.94) 0.01 <0.001
Index60C 0.52 (0.87) –0.41 (0.83) <0.001 <0.001
AStudent’s t test. BMultivariate linear regression with age and BMI Z scores as covariates. CIndex 60 values were log transformed for comparisons. AUC, area 
under the curve; aAb–, autoantibody-negative controls; SD, standard deviation.
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Figure 2. Longitudinal patterns of metabolic decline in Progressors≥5. Shown are the mean values for the fasting C-peptide (A), early C-peptide response 
(B), C-peptide AUC (C), fasting glucose (D), 2-hour glucose (E), glucose AUC, (F) and Index60 (G) at baseline and then each year (±6 months) from 4 years 
to diagnosis for Progressors≥5. Also shown for reference are mean values of the aAb– individuals at baseline (red dotted line). Note that the aAb– control 
group (n = 144) was studied at a single time point, and the dotted line indicates the value obtained at this single time point. The number of Progressors≥5 
with available data at each time point is indicated.
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loss of  β cell function just prior to the baseline observation. On the other hand, loss of  β cell function could 
conceivably have been gradual, but it would have taken time to evolve to such a marked abnormality. Yet 
another explanation is that there is a genetic proclivity for β cell dysfunction that could be independent of  
the immunopathogenesis of  T1D. This would suggest a 2-component causal model for T1D comprising 
constitutional metabolic impairments that act in concert with autoimmunity.
Second metabolic phase. The second metabolic phase was characterized by a pattern of  more gradual 
deterioration. An important consideration is whether this phase represented a period of  immune regulation 
or reflects a relapsing and remitting course of  autoimmunity in T1D (6). Alternatively, these data could 
represent an adaptive period of  pancreatic β cell function, characterized by notable changes in the archi-
tecture of  C-peptide responses with relative preservation of  glycemia. Prior longitudinal analysis of  DPT-1 
data revealed an increase in the late C-peptide OGTT response during T1D progression (2). Similarly, we 
observed an unexpected increase in the C-peptide AUC in the setting of  continued and significant defects 
in the early C-peptide response. This finding is not dissimilar to what is observed in the prediabetic phase 
of  type 2 diabetes (T2D) (7). Whether this response represents the secretory profile of  sick, damaged, or 
dedifferentiated β cells or an adaptive response from subpopulations of  remaining β cells that have escaped 
immune destruction (8, 9) is uncertain but warrants further investigation.
Third metabolic phase. Beginning around 2 years prior to the T1D diagnosis, there was evidence for a third 
metabolic phase, characterized by significant reductions in C-peptide secretion and rising glycemia. The 
majority of  published studies have focused analyses around this particular time point. For example, previous 
longitudinal analyses of  aAb+ individuals followed in the DPT-1 study revealed decreased early C-peptide 
responses during OGTTs and a gradual pattern of  worsening glycemia around 2 years prior to T1D diagno-
sis. Analysis of  the DPT-1 cohort also identified reduced β cell glucose sensitivity around 1.5 years prior to 
T1D onset (2, 3). Our study adds to the previous literature by significantly extending the length of  follow-up 
in the prediagnostic period and by analysis of  participants more heterogeneous in age and geography.
An outstanding question is the pathologic basis for the marked acceleration in β cell dysfunction during 
this terminal phase. The acceleration of  metabolic decline in T1D could be similar to the accelerated patho-
logic decline at the end stage of  other diseases, representing an irremediable threshold effect from chronic 
Table 2. Longitudinal trends of metabolic progression to T1D in Progressors≥5
Baseline to 4 Years Before Diagnosis (n = 48) 4 Years to 1 Year Before Diagnosis (n = 30) 1 Year Before to Diagnosis (n = 27)
Abs Change 
Median (IQR)
%Change 
Median (IQR)
P valueA Abs Change 
Median (IQR)
%Change 
Median (IQR)
P valueA Abs Change 
Median (IQR)
%Change 
Median (IQR)
P valueA
Fasting 
C-peptide  
(ng/ml)
0.23  
(–0.11 to 0.52)
21.61  
(–7.38 to 51.31)
0.001 0.14  
(–0.06 to 0.58)
11.00  
(–2.00 to 37.00)
0.01 0.13  
(–0.23 to 0.81)
5.00  
(–9.00 to 30.00)
0.13
Early 
C-peptide 
Response  
(ng/ml)
–0.18  
(–0.92 to 0.88)
–5.33  
(–30.18 to 33.58)
0.76 –0.43  
(–1.23 to 0.40)
–28.00  
(–42.00 to 11.00)
0.11 –0.44  
(–2.05 to –0.02)
–35.00  
(–47.00 to –2.00)
<0.001
C-Peptide AUC 
(mg/dl/120 
min)
0.11  
(–0.55 to 1.20)
2.34  
(–10.97 to 32.96)
0.32 –0.05  
(–0.57 to 0.69)
–1.00  
(–14.00 to 15.00)
0.90 –0.58  
(–1.58 to 0.09)
–12.00  
(–22.00 to 2.00)
0.01
Fasting 
Glucose  
(mg/dl)
2.50  
(–4.00 to 8.00)
2.89  
(–4.19 to 9.82)
0.02 5.00  
(1.00 to 12.00)
5.00  
(1.00 to 12.00)
0.01 6.00  
(0.00 to 26.00)
7.00  
(0.00 to 25.00)
<0.001
2-hour 
Glucose  
(mg/dl)
7.00  
(–12.00 to 24.00)
5.94  
(–9.38 to 21.12)
0.11 21.5  
(2.00 to 48.00)
21.00  
(2.00 to 43.00)
0.002 85.00  
(60.00 to 
118.00)
62.00  
(30.00 to 95.00)
<0.001
Glucose AUC 7.17  
(–11.50 to 28.58)
5.86  
(–7.35 to 22.59)
0.03 14.21  
(–11.92 to 44.75)
11.00  
(–8.00 to 30.00)
 0.01 39.67  
(20.17 to 64.92)
27.00  
(12.00 to 44.00)
<0.001
Index60 0.15  
(–0.24 to 0.48)
–11.28  
(–91.59 to 40.66)
0.11 0.34  
(–0.09 to 0.97)
1.00  
(–55.00 to 
54.00)
0.004 1.09  
(0.68 to 1.68)
70.00  
(–9.00 to 224.00)
<0.001
AWilcoxon’s signed-rank tests were used to compare absolute changes between the time intervals. Abs, absolute; IQR, interquartile range; AUC, area under 
the curve; T1D, type 1 diabetes.
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β cell loss. Another possibility is these patterns result from a second immunologic hit that precedes this ter-
minal stage of  β cell decline. Notwithstanding this uncertainty, defining the actual reduction in β cell mass 
needed for a diagnosis of  T1D has been challenging and likely differs significantly by individual. Classic 
natural history models invoke a near-complete loss of  β cell mass by the time of  diagnosis. However, more 
recent analysis of  pancreatic sections from persons with established T1D have documented the presence of  
β cells many years after the diagnosis of  T1D, challenging this classic notion. Moreover, β cell mass has been 
shown to be quite variable in those with established disease, while data from aAb+ donors from the nPOD 
collection suggest that β cell mass is relatively preserved in early-stage disease (10–12). Thus, whether this 
terminal decline represents primarily a loss of  β cell function or mass remains unclear. Interestingly, results 
from the Diabetes Virus Detection (DiViD) study demonstrated that ex vivo recovery of  islets obtained via 
pancreatic biopsies from individuals with recent-onset T1D led to improved insulin secretory profiles. While 
insulin secretion remained lower than islets from nondiabetic donors, these data nonetheless indicate that a 
component of  β cell function (as opposed to mass) is reparable in the short term (13).
Our study is the first to our knowledge to identify the presence of  β cell dysfunction so far in advance of  
the diagnosis of  diabetes. The observation that β cell function was already reduced so many years in advance 
of  the diagnosis raises the intriguing possibility that genetic defects in either β cell function, mass, or sur-
vival, are present in some individuals who develop autoimmunity and T1D. Gene variants associated with 
the development of  T1D have been classically associated with altered immune function and self-tolerance. 
However, increased expression of  a number of  these classical T1D risk genes has been identified in cytokine-
stressed β cells, while upregulation of  many of  these genes has been linked with β cell inflammatory and 
apoptotic signaling (14, 15). In contrast to T1D, GWAS studies in T2D have largely identified variants asso-
ciated with impairments in β cell function (16). However, few studies have analyzed whether genes associ-
ated with impaired β cell function in T2D might be similarly associated with T1D. One notable exception is 
transcription factor 7–like 2 (TCF7L2). Polymorphisms in TCF7L2 have been identified in T2D cohorts and 
are associated with impaired insulin secretion and reduced glucagon suppression (16, 17). Recently, variants 
of  TCF7L2 were found to be more frequent in a subset of  individuals diagnosed with T1D in the setting of  
fewer aAbs and decreased frequency of  lower-risk HLA haplotypes (18–20), suggesting that individuals with 
TCF7L2 risk alleles may cross the threshold of  diagnosis in the presence of  a lower immune burden.
In further support of  the notion that β cell susceptibility may contribute to the development of  T1D, a 
number of  studies have analyzed insulin secretion in aAb– relatives of  T1D index cases and found varying 
degrees of  β cell dysfunction (21–23). While these data suggest the possibility that T1D kindreds may have 
preexisting impairments in β cell function, they also highlight one potential limitation of  our control group. 
We utilized data from first-, second-, and third-degree relatives who underwent oral glucose tolerance testing 
Table 3. Comparison of longitudinal trends between Progressors≥5 and Progressors<5
3 Years Prior to T1D (±6 months) 2 Years Prior to T1D (±6 months) 1 year Prior to T1D (±6 months)
Variable Progressors≥5  
(n = 29) Mean (SD)
Progressors<5  
(n = 72) Mean (SD)
Progressors≥5  
(n = 29) Mean (SD)
Progressors<5  
(n = 72) Mean (SD)
Progressors≥5  
(n = 29) Mean (SD)
Progressors<5  
(n = 72) Mean (SD)
Fasting C-peptide 
(ng/ml)
1.67 (0.92) 1.43 (0.64) 1.88 (0.88) 1.59 (0.81) 1.90 (0.99) 1.68 (0.75)
Early C-peptide 
Response (ng/ml)
2.89 (1.49) 3.07 (1.66) 2.74 (1.55) 2.64 (1.50) 2.75 (1.80) 2.61 (1.37)
C-Peptide AUC  
(mg/dl/120 min)
5.32 (2.09) 4.90 (1.76) 5.74 (2.18) 5.00 (2.07) 5.79 (2.85) 5.0 (1.89)
Fasting Glucose 
(mg/dl)
89.14 (10.96) 89.43 (9.11) 93.55 (11.22) 90.01 (11.89) 94.69 (12.47) 92.83 (11.65)
2-hour Glucose  
(mg/dl)
127.66 (25.3) 129.64 (28.12) 142.45 (34.24) 136.35 (31.87) 153.14 (33.31) 151.13 (38.78)
Glucose AUC 147.27 (20.59) 143.37 (21.59) 158.15 (27.27) 152.36 (24.92) 166.14 (25.54) 161.7 (26.24)
Index60A 0.69 (0.91) 0.69 (0.79) 0.90 (0.94) 0.92 (0.85) 1.03 (1.06) 1.14 (0.93)
No significant differences between the groups were found at any time point using Student’s t tests or multivariate linear regression with adjustment for 
age and BMI Z scores. Analysis limited to Progressors≥5 and Progressors<5 who had all 3 OGTTs. AIndex60 values were log transformed for comparisons. 
AUC, area under the curve; SD, standard deviation; T1D, type 1 diabetes.
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around the time of  a negative aAb screen. While we still observed large differences between Progressors≥5 
and the control group, it is possible that even more substantial differences would be present using a control 
group comprising individuals unrelated to persons with T1D.
Finally, it is necessary to consider how representative Progressors≥5 are of  all individuals diagnosed 
with T1D. Progressors≥5 comprised 13.7% of  analyzed diabetes cases within the cohort. Because aAb+ 
individuals are enrolled into TrialNet in a cross-sectional manner, we do not know the true duration of  aAb 
positivity prior to the initial aAb+ screen. As such, this likely represents a minimum estimate of  the number 
of  individuals who have aAb positivity for 5 or more years before T1D diagnosis. Metabolic dysfunction 
may have been present for a substantially longer period of  time in some Progressors≥5 and certainly may 
have been present for longer in Progressors<5. However, a striking finding of  our analysis was the great 
deal of  similarity in the degree and patterns of  β cell dysfunction during the last 3 years before diagno-
sis between Progressors≥5 and Progressors<5. These findings suggest that, despite differences in age and 
potentially length of  aAb positivity, there may be a characteristic pattern of  decline in β cell function within 
3 years of  clinical diagnosis. The number of  subjects who had metabolic data at each of  the specified time 
points shown in Table 3 and Supplemental Table 3 was limited. Therefore, it would be of  interest to deter-
mine whether this similar pattern can be corroborated in other populations, including birth cohorts that are 
followed both before and after seroconversion.
Taken together, these data provide insight into the chronicity of  β cell dysfunction in T1D and provide 
what we believe to be a new nomenclature for describing 3 distinct metabolic phases of  T1D evolution. We 
also establish a hierarchy of  β cell decline that should be considered for the purposes of  risk stratification 
and when designing interventions that test disease-modifying therapies.
Methods
aAb+ participants and follow-up. Criteria for entry into the TrialNet PTP cohort have been previously 
described in detail (24). In brief, nondiabetic first-, second-, or third-degree relatives of  individuals with 
T1D (proband) were screened for the presence of  aAbs specific for pancreatic islets. aAb status was 
assessed using procedures outlined previously in the Diabetes Antibody Standardization Program (25). 
Initial testing for glutamic acid decarboxylase 65 (GAD65), microinsulin aAb assay (mIAA), or islet-anti-
gen 2 (IA-2/ICA512) aAbs was followed by measurement of  islet cell (ICA) or zinc transporter 8 (ZnT8) 
aAbs if  any one initial test was positive (26). ZnT8 was measured in a limited group of  PTP participants 
beginning in 2004 (27), and measurement of  ZnT8 for the entire PTP cohort began in 2012. From 2004 
through 12/31/2016, a total of  180,452 individuals were screened for the presence of  these aAbs against 
β cell antigens. The majority (n = 174,929) were identified as aAb–, whereas 5,523 individuals (3%) were 
identified as either confirmed single or multiple aAb+ and enrolled for longitudinal monitoring (Figure 
1). Longitudinal monitoring of  aAb+ individuals consisted of  semiannual or annual study visits that 
included a standard protocol 2-hour OGTT (28). Glucose was measured using the glucose oxidase meth-
od (29); C-peptide was measured using a 2-site immunoenzymometric assay performed on a Tosoh II 600 
autoanalyzer (30). Diabetes was diagnosed according to American Diabetes Association criteria (31). A 
total of  1,032 subjects within the PTP cohort have been diagnosed with T1D; 483 were excluded from this 
analysis. These included subjects with a diabetic OGTT at study entry, incomplete baseline OGTT data, 
previous participation in the DPT-1 study, or current participation in a prevention trial.
aAb– participants. Since 2008, 144 relatives of  T1D patients having no positive aAbs in the first screen-
ing sample were selected for enrollment into an aAb– control group. These individuals underwent a 2-hour 
OGTT shortly after the negative aAb screening.
Statistics. To compare demographic characteristics between groups,  Pearson’s χ2 test was used for 
categorical data. For comparisons of  continuous data, ANOVA tests were used to compare means, 
while Kruskal-Wallis tests were used to compare medians. Metabolic parameters were derived from 
OGTTs. The early C-peptide response was defined as the difference between the 30- and 0-minute 
C-peptide values. Glucose and C-peptide AUCs were defined as total area under the 2-hour OGTT 
curve, calculated using the trapezoid rule, and then divided by 120 minutes. The Index60 was cal-
culated according to the following formula: Index60 = (0.3695 × log fasting C-peptide) + (0.0165 × 
60-minute glucose) – (0.3644 × 60-minute C-peptide) (32). Metabolic parameters between groups were 
compared using Student’s t tests and a multivariate linear regression model with adjustment for age 
and BMI Z score. Index60 values were log transformed before comparisons. Changes in metabolic 
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parameters over time were assessed using a general linear mixed model. The absolute change between 
2 time points was calculated as the value at the later time point minus the value at the earlier time 
point; the percentage change between 2 time points was calculated as the difference between 2 time 
points divided by the value at the earlier time point, which was multiplied by 100. Paired t tests were 
used to assess significant change in metabolic parameters between 2 time points. When the sample size 
was less than 30, a nonparametric Wilcoxon’s signed-rank test was used. Unpaired t tests and Mann-
Whitney tests were used to analyze between-group differences (Progressors≥5 vs. Progressors<5). Sta-
tistical analyses were performed with SAS (version 9.4; SAS Institute). All tests of  significance were 
2 tailed, and P values < 0.05 were considered statistically significant. P values were not adjusted for 
multiple testing, as our a priori intent was to test each variable independently.
Study approval. All human studies were approved by participating institutional review boards and writ-
ten informed consent was received from participants prior to inclusion in the study.
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